Drug Trial Radar · NCT03760003
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
Last checked: Nov 19, 2026Latest source record: Nov 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
355
Actual
Start
Aug 13, 2019
Primary completion
Apr 1, 2021
Study completion Apr 16, 2021
Sponsor
- Lead sponsor
- Abivax S.A.Industry
- Sponsor type
- Industry
- First posted
- Nov 30, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 2b study to evaluate the efficacy and the safety of 3 dose-levels of ABX464, administered daily in patients with moderate to severe Ulcerative Colitis.
Conditions
- Ulcerative Colitis
Interventions
ABX464 100 mgDrug
ABX464 100 mg (two capsules of ABX464 50 mg) once daily for 16 weeks
ABX464 50 mgDrug
ABX464 50 mg (one capsule of ABX464 50 mg + one capsule of placebo) once daily for 16 weeks
ABX464 25 mgDrug
ABX464 25 mg (one capsule of ABX464 25 mg + one capsule of placebo) once daily for 16 weeks
PlaceboDrug
Two capsules of placebo once daily for 16 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduction From Baseline in Modified Mayo Score (MMS) at Week 8Time frame: Week 8
Locations
130 sites in 17 countries. Site status is shown where the registry gives one.
UCSD Health System
San Diego, California
Atlanta Center for Gastroenterology, P.C
Decatur, Georgia
Central Texas Clinical Research, LLC
Austin, Texas
Southern Star Research Institute, LLC
San Antonio, Texas
Medizinische Universität Innsbruck
Innsbruck, Austria
Klinikum Klagenfurt am Wörthersee
Klagenfurt, Austria
Ordensklinikum Linz GmbH - Barmherzige Schwestern
Linz, Austria
AKH - Medizinische Universität Wien
Vienna, Austria
Gomel Regional Clinical Hospital
Homyel, Belarus
Minsk city diagnostic center
Minsk, Belarus
Regional Clinical Hospital
Minsk, Belarus
Vitebsk Regional Clinical Hospital
Vitebsk, Belarus
Vitebsk regoinal clinical specialized center
Vitebsk, Belarus
AZ Sint-Lucas
Bruges, Belgium
C. H. U. St-Pierre
Brussels, Belgium
UZA
Edegem, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
UZ Leuven
Leuven, Belgium
Brandon Medical Arts Clinic
Brandon, Canada
South Edmonton Gastroenterology
Edmonton, Canada
LHSC - Victoria Hospital
London, Canada
The Ottawa Hospital - General Campus
Ottawa, Canada
Allen Whey Khye Lim Professional Corporation
Saskatoon, Canada
Mount Sinai Hospital
Toronto, Canada
Fakultni nemocnice u sv. Anny v Brne
Brno, Czechia
Hepato-Gastroenterologie HK s.r.o.
Hradec Králové, Czechia
MUDr. GREGAR s.r.o.
Olomouc, Czechia
Fakultni nemocnice Ostrava
Ostrava-Kunčice, Czechia
Nemocnice Na Bulovce
Prague, Czechia
Thomayerova nemocnice
Prague, Czechia
Nemocnice Slany
Slaný, Czechia
CHU Amiens - Hopital Sud
Amiens, France
CHU Besançon - Hôpital Jean Minjoz
Besançon, France
CHU Clermont Ferrand - Hôpital d'Estaing
Clermont-Ferrand, France
Hôpital Beaujon
Clichy, France
CHU de Grenoble - Hôpital Nord
Grenoble, France
Centre Hospitalier Départemental Les Oudairies
La Roche-sur-Yon, France
CHU Lille - Hôpital Claude Huriez
Lille, France
Hôpital Nord - CHU Marseille
Marseille, France
Hopital Saint Eloi
Montpellier, France
Showing 40 of 130 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.